Shin Nippon Biomedical Laboratories, Ltd. (FRA:YB3)

Market Cap	349.00M -7.2%
Revenue (ttm)	182.64M +1.7%
Net Income	28.92M +6.1%
EPS	0.73 +6.1%
Shares Out	n/a
PE Ratio	11.31
Forward PE	n/a
Dividend	0.27 (3.31%)
Ex-Dividend Date	Sep 29, 2026

Volume	1,000
Open	8.30
Previous Close	8.20
Day's Range	8.30 - 8.30
52-Week Range	5.70 - 10.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 10, 2026

About FRA:YB3

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies. The company also engages in licensing activities for proprietary products which utilize unique intranasal formulation...

• Industry: Commercial Physical and Biological Research
• Sector: Healthcare
• Founded: 1957
• Employees: 1,680
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: YB3

Financial Performance

In fiscal year 2026, FRA:YB3's revenue was 32.52 billion, an increase of 0.34% compared to the previous year's 32.41 billion. Earnings were 4.57 billion, a decrease of -7.27%.

Financial numbers in JPY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error